Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients.
Standard
Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients. / Brack, T; Scholz, R B; Milde-Langosch, K; Heinsohn, S; Löning, Thomas; Kabisch, H.
In: CANCER DETECT PREV, Vol. 16, No. 3, 3, 1992, p. 185-192.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Detection of N-myc gene amplification in bone marrow specimen of stage IV neuroblastoma patients.
AU - Brack, T
AU - Scholz, R B
AU - Milde-Langosch, K
AU - Heinsohn, S
AU - Löning, Thomas
AU - Kabisch, H
PY - 1992
Y1 - 1992
N2 - N-myc gene amplification is an unfavorable prognostic factor in neuroblastoma; therefore, its detection might have therapeutical consequences. Because of the reliability of noninvasive diagnostic methods such as X-ray examination and measurement of vanilymandelic acid and the lack of technical unavailability at most institutions, the determination of the N-myc status of neuroblastoma often is not done. In our investigation of 14 neuroblastoma patients, we could demonstrate N-myc gene amplification in the bone marrow of 5 patients with neuroblastoma stage IV disease and in bone marrow infiltration without enrichment of neuroblastoma cells. Otherwise, no information about the tumor content of N-myc gene copies at the time of initial diagnosis could be obtained. At the subsequent resection, the N-myc gene amplification was confirmed by the additional Southern blot analysis and in situ hybridization of tumor tissue. Furthermore, the N-myc status of bone marrow was analyzed during the stages of chemotherapy in three cases.
AB - N-myc gene amplification is an unfavorable prognostic factor in neuroblastoma; therefore, its detection might have therapeutical consequences. Because of the reliability of noninvasive diagnostic methods such as X-ray examination and measurement of vanilymandelic acid and the lack of technical unavailability at most institutions, the determination of the N-myc status of neuroblastoma often is not done. In our investigation of 14 neuroblastoma patients, we could demonstrate N-myc gene amplification in the bone marrow of 5 patients with neuroblastoma stage IV disease and in bone marrow infiltration without enrichment of neuroblastoma cells. Otherwise, no information about the tumor content of N-myc gene copies at the time of initial diagnosis could be obtained. At the subsequent resection, the N-myc gene amplification was confirmed by the additional Southern blot analysis and in situ hybridization of tumor tissue. Furthermore, the N-myc status of bone marrow was analyzed during the stages of chemotherapy in three cases.
M3 - SCORING: Zeitschriftenaufsatz
VL - 16
SP - 185
EP - 192
IS - 3
M1 - 3
ER -
